ICON plc, a world-leading clinical research organisation, today released findings from two biotech sector surveys. The first survey focused on global biotech trends and is an update of our 2023…
AskBio’s AB-1005 and AB-1002 Granted Pioneering Regenerative Medicine Product Designation in Japan AskBio Inc., a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, today…
CVS Health Revises Financial Outlook, Showcases Business Strength, and Unveils Bold Strategy to Redefine Health Care at Investor Day CVS Health® will launch its strategy to deliver best-in-class execution, transform…
BioNTech and Bristol Myers Squibb Unveil Promising Phase 2 Global Data for Pumitamig—First PD-L1xVEGF-A Bispecific Antibody—Demonstrating Encouraging Efficacy in Advanced Triple-Negative Breast Cancer BioNTech SE and Bristol Myers Squibb Company today announced the…
Novartis’ Ianalumab Provides Sustained Disease Control in Immune Thrombocytopenia Patients with Just Four Monthly Doses Novartis today announced positive results from VAYHIT2, a Phase III trial evaluating ianalumab plus eltrombopag in…
Roche Introduces New CE-Marked PCR Test to Enhance Diagnostic Accuracy for Women with Vaginitis Roche announced today the CE Mark for its cobas® BV/CV (Bacterial Vaginosis/Candida Vaginitis) assay to accurately…
Phase 3 MajesTEC-3 Study Delivers Unprecedented Results, Positioning TECVAYLI® Plus DARZALEX FASPRO® as a Potential New Standard of Care as Early as Second-Line Treatment for Relapsed/Refractory Multiple Myeloma Johnson &…
Lilly to Invest $6 Billion in Alabama Facility for Active Pharmaceutical Ingredient Production Eli Lilly and Company today announced plans to invest more than $6 billion in a new manufacturing facility in Huntsville, Alabama.…
Jim Lang Elected to Halozyme’s Board of Directors Halozyme Therapeutics, Inc. today announced the election of Jim Lang to its Board of Directors. Mr. Lang brings more than 30 years of…
Global health leaders convene at the IAEA headquarters in Vienna this week to advance radiation safety in medicine The International Conference on Radiation Protection in Medicine: X Ray Vision, organized by…
Genmab Unveils New Phase 1b/2 EPCORE® CLL-1 Data Showcasing Epcoritamab’s Promise as Monotherapy and in Combination for Richter Transformation Patients Genmab A/S today announced new and updated data from three arms of the ongoing Phase 1b/2 EPCORE® CLL-1 trial evaluating the efficacy and…
BRUKINSA Achieves Landmark 74% Six-Year Progression-Free Survival in Treatment-Naïve Chronic Lymphocytic Leukemia Patients BeOne Medicines Ltd., a global oncology company, reaffirms its position as the leader in chronic lymphocytic leukemia…